» Articles » PMID: 32419823

A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix

Overview
Date 2020 May 19
PMID 32419823
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Dipsaci Radix (DR) has been used to treat fracture and osteoporosis. Recent reports have shown that myeloid cells from bone marrow can promote the proliferation of lung cancer. However, the action and mechanism of DR has not been well defined in lung cancer. The aim of the present study was to define molecular mechanisms of DR as a potential therapeutic approach to treat lung cancer.

Methods: Active compounds of DR with oral bioavailability ≥30% and drug-likeness index ≥0.18 were obtained from the traditional Chinese medicine systems pharmacology database and analysis platform. The potential target genes of the active compounds and bone were identified by PharmMapper and GeneCards, respectively. The compound-target network and protein-protein interaction network were built by Cytoscape software and Search Tool for the Retrieval of Interacting Genes webserver, respectively. GO analysis and pathway enrichment analysis were performed using software.

Results: Our study demonstrated that DR had 6 active compounds, including gentisin, sitosterol, Sylvestroside III, 3,5-Di-O-caffeoylquinic acid, cauloside A, and japonine. There were 254 target genes related to these active compounds as well as to bone. SRC, AKT1, and GRB2 were the top 3 hub genes. Metabolisms and signaling pathways associated with these hub genes were significantly enriched.

Conclusions: This study indicated that DR could exhibit the anti-lung cancer effect by affecting multiple targets and multiple pathways. It reflects the traditional Chinese medicine characterized by multicomponents and multitargets. DR could be considered as a candidate for clinical anticancer therapy by regulating bone physiological functions.

Citing Articles

Expression of lncRNA LINC00943 in lung squamous cell carcinoma and its relationship with tumor progression.

Zhao Z, Li H, Li J, Rong Y, Zhao L, Hao M J Cardiothorac Surg. 2024; 19(1):222.

PMID: 38627774 PMC: 11020474. DOI: 10.1186/s13019-024-02771-2.


Core Constituents of for Rheumatoid Arthritis Treatment and the Potential Mechanism.

Qu B, Wang S, Zhu H, Yin T, Zhou R, Hu W ACS Omega. 2023; 8(2):2586-2595.

PMID: 36687056 PMC: 9851025. DOI: 10.1021/acsomega.2c07094.


Regulatory mechanism of Georgi on bone cancer pain based on network pharmacology and experimental verification.

Wang A, Guo D, Cheng H, Jiang H, Liu X, Tie M PeerJ. 2022; 10:e14394.

PMID: 36415861 PMC: 9676018. DOI: 10.7717/peerj.14394.


Osteoporosis in Patients With Respiratory Diseases.

Ma Y, Qiu S, Zhou R Front Physiol. 2022; 13:939253.

PMID: 35903070 PMC: 9315364. DOI: 10.3389/fphys.2022.939253.

References
1.
Niu Y, Li C, Pan Y, Li Y, Kong X, Wang S . Treatment of Radix Dipsaci extract prevents long bone loss induced by modeled microgravity in hindlimb unloading rats. Pharm Biol. 2014; 53(1):110-6. DOI: 10.3109/13880209.2014.911920. View

2.
Brown G, Marchwicka A, Cunningham A, Toellner K, Marcinkowska E . Antagonizing Retinoic Acid Receptors Increases Myeloid Cell Production by Cultured Human Hematopoietic Stem Cells. Arch Immunol Ther Exp (Warsz). 2016; 65(1):69-81. PMC: 5274652. DOI: 10.1007/s00005-016-0411-0. View

3.
Sayeed M, Ameen S . Beta-Sitosterol: A Promising but Orphan Nutraceutical to Fight Against Cancer. Nutr Cancer. 2015; 67(8):1214-20. DOI: 10.1080/01635581.2015.1087042. View

4.
Wong R, Rabie A, Hagg E . The effect of crude extract from Radix Dipsaci on bone in mice. Phytother Res. 2007; 21(6):596-8. DOI: 10.1002/ptr.2126. View

5.
Zang R, Shi J, Lerut T, Wang L, Liu C, Brunelli A . Ten-Year Trends of Clinicopathologic Features and Surgical Treatment of Lung Cancer in China. Ann Thorac Surg. 2019; 109(2):389-395. DOI: 10.1016/j.athoracsur.2019.08.017. View